IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor: Cynthia B. ROBINSON, et al.

Serial Number: 10/698,080

Filing Date: October 29, 2003

Title: COMBINATION OF

DEHYDROEPIANDROSTERONE OR DEHYDROEPIANDROSTERONE-SULFATE WITH A LIPOXYGENASE INHIBITOR FOR TREATMENT OF

ASTHMA OR CHRONIC OBSTRUCTIVE

PULMONARY DISEASE

Group Art Unit: 1617

Examiner: Kevin J. Capps

CONFIRMATION NO: 9176

FILED ELECTRONICALLY ON: December 15, 2006

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.97

Sir:

Applicants hereby submit an Information Disclosure Statement along with attached form PTO/SB/08. A copy of each listed publication is submitted, if required, pursuant to 37 CFR §§1.97-1.98, as indicated below.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. Applicants further request that the Examiner initial and return the attached form PTO/SB/08 in accordance with MPEP §609.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, prior art or material to patentability as defined in §1.56.

3012862_1.DOC

because: $37 \ CFR \ \S 1.9/(b)$. This information Disclosure Statement should be considered by the				
		(1)	It is being filed within 3 months of the filing date of a national application and is other than a continued prosecution application under §1.53(d);	
			OR	
		(2)	It is being filed within 3 months of entry of the national stage as set forth in §1.491 in an international application;	
			OR	
	\boxtimes	(3)	It is being filed before the mailing of a first Office action on the merits;	
			OR	
		(4)	It is being filed before the mailing of a first Office action after the filing of a request for continued examination under §1.114.	
B. 37 CFR §1.97(c). Although this Information Disclosure Statement is being filed after the perspecified in 37 CFR §1.97(b), above, it is filed before the mailing date of the earlier of (1) a fit office action under §1.113, (2) a notice of allowance under §1.311, or (3) an action that otherw closes prosecution on the merits, this Information Disclosure Statement should be considered because it is accompanied by one of:				
		a stat	tement as specified in §1.97(e) provided concurrently herewith;	
			OR	
			of \$180.00 as set forth in \$1.17(p) authorized below, enclosed, or included with the nent of other papers filed together with this statement.	
C.	date of the	earlie	7(d). Although this Information Disclosure Statement is being filed after the mailing r of (1) a final office action under §1.113 or (2) a notice of allowance under §1.311, before payment of the issue fee and should be considered because it is accompanied	
		i. a	statement as specified in §1.97(e);	
			AND	
			fee of \$180.00 as set forth in \$1.17(p) is authorized below, enclosed, or included with the payment of other papers filed together with this Statement.	
D.	☐ 37 CF.	R §1.9	7(e). Statement.	
		A sta	atement is provided herewith to satisfy the requirement under 37 CFR §§1.97(c);	
			AND/OR	
		A sta	atement is provided herewith to satisfy the requirement under 37 CFR §§1.97(d);	
			AND/OR	
		infor	ppy of a dated communication from a foreign patent office clearly showing that the mation disclosure statement is being submitted within 3 months of the filing date on communication is provided in lieu of a statement under 37 C.F.R. § 1.97(e)(1) as ided for under MPEP 609.04(b) V.	
E.	disclosure application	statem that v	inder 37 C.F.R. §1.704(d). Each item of information contained in the information nent was first cited in a communication from a foreign patent office in a counterpart was received by an individual designated in § 1.56(c) not more than thirty (30) days g of this information disclosure statement. This statement is made pursuant to the	

for Applicant(s) delay. F. \boxtimes 37 CFR §1.98(a)(2). The content of the Information Disclosure Statement is as follows: Copies of each of the references listed on the attached Form PTO/SB/08 are enclosed herewith. -- OR --Copies of U.S. Patent Documents (issued patents and patent publications) listed on the \boxtimes attached Form PTO/SB/08 are NOT enclosed. -- AND/OR --Copies of Foreign Patent Documents and/or Non Patent Literature Documents listed on M the attached Form PTO/SB/08 are enclosed in accordance with 37 CFR §1.98 (a)(2). -- AND/OR --Copies of pending unpublished U.S. patent applications are enclosed in accordance with 37 CFR §1.98(a)(2)(iii). G. \square 37 CFR §1.98(a)(3). The Information Disclosure Statement includes non-English patents and/or references. Pursuant to 37 CFR §1.98(a)(3)(i), a concise explanation of the relevance of each patent, publication or other information provided that is not in English is provided herewith. Pursuant to MPEP 609(B), an English language copy of a foreign search report is submitted herewith to satisfy the requirement for a concise explanation where non-English language information is cited in the search report. -- OR --A concise explanation of the relevance of each patent, publication or other information provided that is not in English is as follows: Pursuant to 37 CFR §1.98(a)(3)(ii), a copy of a translation, or a portion thereof, of the П non-English language reference(s) is provided herewith. H. [37 CFR §1.98(d). Copies of patents, publications and pending U.S. patent applications, or other information specified in 37 C.F.R. § 1.98(a) are not provided herewith because: Pursuant to 37 CFR §1.98(d)(1) the information was previously submitted in an Information Disclosure Statement for another application under which this application claims priority for an earlier effective filing date under 35 U.S.C. 120. Application in which the information was submitted: Information Disclosure Statement(s) filed on: AND The information disclosure statement submitted in the earlier application complied with paragraphs (a) through (c) of 37 CFR §1.98.

requirements of 37 C.F.R. §1.704(d) to avoid reduction of the period of adjustment of the patent term

Respectfully submitted,

WILSON SONSINI GOODRICH & ROSATI

Dated: December 15, 2006

650 Page Mill Road Palo Alto, CA 94304-1050 (650) 493-9300 Customer No. 021971

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known 10/698.080 Application Number Substitute for form 1449/PTO October 29, 2003 Filing Date

INFORMATION DISCLOSURE First Named Inventor Cynthia B. Robinson STATEMENT BY APPLICANT (Use as many sheets as necessary) Art Unit 1617 **Examiner Name** Kevin J. Capps Of 30775-718.201 2 Attorney Docket Number Sheet

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (If known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	1.	US 2002/0032160	03/14/2002	Nyce		
<u> </u>						
					<u>. </u>	
		1				

	FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ – Number ⁴ – Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶	
	:						

Examiner	Date		
Signature	Considered		

check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

15 you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 'Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 'For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 'Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 'Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08 (07/05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

30775-718.201

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known 10/698.080 **Application Number** Substitute for form 1449/PTO Filing Date October 29, 2003 INFORMATION DISCLOSURE Cynthia B. Robinson First Named Inventor STATEMENT BY APPLICANT (Use as many sheets as necessary) Art Unit 1617 **Examiner Name** Kevin J. Capps

Attorney Docket Number

Of

Sheet

2

Examiner Initials*					
	2.	CRETICOS, P. S. Managing asthma in adults. Am J Manag Care. 2000; 6(17 Suppl):S940-63.			

Examiner		ate	
Signature	Co	onsidered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.